<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00009750</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000068364</org_study_id>
    <secondary_id>UCD-992126</secondary_id>
    <secondary_id>NCI-V00-1639</secondary_id>
    <nct_id>NCT00009750</nct_id>
  </id_info>
  <brief_title>Monoclonal Antibody Therapy Plus Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy</brief_title>
  <official_title>Combined Modality Radioimmunotherapy For Hormone Refractory Metastatic Prostate Cancer With Two Cycles Of Escalating Dose 90Y-DOTA-Peptide-m170 And Fixed, Low Dose Paclitaxel With Blood Stem Cell Support And Cyclosporin For HAMA Suppression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Davis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Radiolabeled monoclonal antibodies can locate tumor cells and either kill them or&#xD;
      deliver tumor-killing substances to them without harming normal cells. Drugs used in&#xD;
      chemotherapy use different ways to stop tumor cells from dividing so they stop growing or&#xD;
      die. Combining monoclonal antibody therapy and chemotherapy with peripheral stem cell&#xD;
      transplantation may be an effective treatment for metastatic prostate cancer.&#xD;
&#xD;
      PURPOSE: Phase I trial to study the effectiveness of monoclonal antibody therapy plus&#xD;
      chemotherapy followed by peripheral stem cell transplantation in treating patients who have&#xD;
      metastatic prostate cancer that has not responded to hormone therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the maximum tolerated dose of yttrium Y90 monoclonal antibody m170&#xD;
           administered with paclitaxel and cyclosporine followed by autologous peripheral blood&#xD;
           stem cell transplantation in patients with hormone-refractory metastatic prostate&#xD;
           cancer.&#xD;
&#xD;
        -  Determine the preliminary efficacy of this regimen in these patients.&#xD;
&#xD;
      OUTLINE: This is an open-label, dose-escalation study of yttrium Y 90 monoclonal antibody&#xD;
      m170 (Y90 MOAB m170). Patients are assigned to one of four cohorts.&#xD;
&#xD;
      After the first occurrence of hematologic dose-limiting toxicity in a patient, all subsequent&#xD;
      patients receive filgrastim (G-CSF) subcutaneously (SC) beginning 4 days prior to undergoing&#xD;
      apheresis and continuing until 6 million CD34+ cells/kg are collected. After 2 patients in a&#xD;
      cohort group experience hematologic dose-limiting toxicity, subsequent patients undergo&#xD;
      autologous peripheral blood stem cell (PBSC) transplantation.&#xD;
&#xD;
        -  Cohort I: Patients receive unlabeled monoclonal antibody (MOAB) m170 IV over 5 minutes&#xD;
           followed by a tracer dose of indium In 111 monoclonal antibody m170 (In111 MOAB m170) IV&#xD;
           over 5-10 minutes on day 0 and unlabeled MOAB m170 IV followed by Y90 MOAB m170 IV on&#xD;
           day 7. Patients also receive oral cyclosporine every 12 hours on days -3 to 25. Patients&#xD;
           may undergo autologous PBSC transplantation on day 21 and receive G-CSF SC daily&#xD;
           beginning on day 21 and continuing until blood counts recover.&#xD;
&#xD;
        -  Cohort II: Patients receive treatment as in cohort I. Patients also receive paclitaxel&#xD;
           IV over 3 hours on day 9.&#xD;
&#xD;
        -  Cohort III and IV: Patients receive treatment as in cohort I without In111 MOAB m170.&#xD;
           Patients also receive paclitaxel as in cohort II.&#xD;
&#xD;
      Cohorts of 3 to 6 patients receive escalating doses of Y90 MOAB m170 until the maximum&#xD;
      tolerated dose (MTD) is determined. The MTD is defined as the dose at which 2 of 3 or 2 of 6&#xD;
      patients experience dose-limiting toxicity.&#xD;
&#xD;
      Patients are followed monthly for 3 months, every 3 months for 1 year, and then every 6&#xD;
      months for 1 year.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 18-30 patients will be accrued for this study within 36 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>March 2001</start_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Prostate Cancer</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>monoclonal antibody m170</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclosporine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>indium In 111 monoclonal antibody m170</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>yttrium Y 90 monoclonal antibody m170</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed hormone-refractory metastatic prostate&#xD;
             cancer&#xD;
&#xD;
          -  Hormonal ablation (surgical or chemical) at least 3 months prior to study&#xD;
&#xD;
          -  HAMA titer negative&#xD;
&#xD;
          -  Less than 25% bone marrow involvement by metastatic prostate cancer&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Karnofsky 70-100%&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,00/mm^3&#xD;
&#xD;
          -  Hemoglobin at least 10.0 g/dL (without transfusion)&#xD;
&#xD;
          -  No chronic transfusion requirement&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 1.3 mg/dL&#xD;
&#xD;
          -  AST no greater than 1.5 times normal&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine less than 1.5 mg/dL&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  LVEF at least 50% by MUGA&#xD;
&#xD;
          -  No disseminated intravascular coagulation&#xD;
&#xD;
        Pulmonary:&#xD;
&#xD;
          -  FEV1 at least 65% of predicted&#xD;
&#xD;
          -  FVC at least 65% of predicted&#xD;
&#xD;
          -  Corrected DLCO at least 60%&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  No prior murine protein (e.g., ProstaScint)&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  At least 4 weeks since prior standard dose chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  At least 4 weeks since prior external beam radiotherapy&#xD;
&#xD;
          -  No prior radiotherapy to no more than 25% of total skeleton&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No concurrent oral anticoagulants (low dose coumadin for central line thrombosis&#xD;
             prophylaxis allowed)&#xD;
&#xD;
          -  No concurrent chronic transfusions&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carol M. Richman, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of California, Davis</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California Davis Cancer Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2003</verification_date>
  <study_first_submitted>February 2, 2001</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>September 19, 2013</last_update_submitted>
  <last_update_submitted_qc>September 19, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 20, 2013</last_update_posted>
  <keyword>stage IV prostate cancer</keyword>
  <keyword>recurrent prostate cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Antineoplastic Agents, Immunological</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

